Lefer A M
Klin Wochenschr. 1982 Jul 15;60(14):713-6. doi: 10.1007/BF01716561.
Myocardial Depressant Factor (MDF) is a small peptide circulating in the blood of all mammalian species tested in a variety of shock states including endotoxic, hemorrhagic, cardiogenic, bowel ischemic, acute pancreatitis, burn, and traumatic shock. MDF is produced by the action of proteolytic enzymes released by the ischemic pancreas. MDF acts to depress myocardial contractility, constrict the splanchnic arteries and impair reticuloendothelial system phagocytosis. Several pharmacologic agents prevent the formation of MDF including membrane stabilizers (e.g., glucocorticoids), protease inhibitors (e.g., aprotinin), converting enzyme inhibitors (e.g., captopril), prostaglandins (e.g., PGE1 and PGI2), thromboxane synthetase inhibitors (e.g., imidazole, PTA2) and local anesthetics (e.g., lidocaine). Prevention of MDF formation or action improves survival. Thus, MDF is an important mediator of shock pathophysiology and should be considered in the therapy of circulatory shock states.
心肌抑制因子（MDF）是一种小肽，在多种休克状态下接受测试的所有哺乳动物物种的血液中循环，这些休克状态包括内毒素性休克、失血性休克、心源性休克、肠道缺血性休克、急性胰腺炎、烧伤和创伤性休克。MDF是由缺血胰腺释放的蛋白水解酶作用产生的。MDF的作用是抑制心肌收缩力、收缩内脏动脉并损害网状内皮系统的吞噬作用。几种药物制剂可防止MDF的形成，包括膜稳定剂（如糖皮质激素）、蛋白酶抑制剂（如抑肽酶）、转化酶抑制剂（如卡托普利）、前列腺素（如PGE1和PGI2）、血栓素合成酶抑制剂（如咪唑、PTA2）和局部麻醉剂（如利多卡因）。预防MDF的形成或作用可提高生存率。因此，MDF是休克病理生理学的重要介质，在循环性休克状态的治疗中应予以考虑。
